Oramed Pharmaceuticals Inc. has entered into binding agreements with Lifeward Ltd. to transfer its proprietary Protein Oral Drug (POD™) delivery technology to Lifeward. As part of the transaction, Oramed will receive a 49.9% beneficial ownership interest in Lifeward, along with warrants. Oramed will continue to manage and fund the upcoming clinical trial for the oral delivery platform. In addition, Oramed will receive 4% of net sales from Lifeward’s ReWalk franchise for up to 10 years. Lifeward will issue $10 million in senior secured convertible notes, with Oramed investing $9 million, and has generated $26 million in revenue from its FDA-approved ReWalk® and AlterG® products in the last four quarters. The transaction is expected to advance the oral insulin program and further diversify Lifeward’s biomedical innovation portfolio.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oramed Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-004382), on January 14, 2026, and is solely responsible for the information contained therein.